Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance

• Tatebe Yasuhisa

• Kanamitsu Kiichiro

• Kanzaki Hirotaka

• Ishida Hisashi

• Fujiwara Kaori

• Washio Kana

• Kitamura Yoshihisa

• Sendo Toshiaki

• Shimada Akira

• Tsukahara Hirokazu

抄録

Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and clearance. Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated with methotrexate elimination. We present a case of a pediatric patient with acute lymphoblastic leukemia who suffered from persistently high plasma methotrexate concentrations and acute kidney injuries after the admin-istration of a medium dose of methotrexate. Subsequent genetic analysis showed that he was a carrier of dys-functional genetic variants associated with methotrexate clearance. This case highlights that polymorphisms of methotrexate transporter pathways can adversely affect methotrexate elimination in a clinically significant manner.

収録刊行物

• Acta Medica Okayama

  Acta Medica Okayama 74 (6), 545-550, 2020-12

  Okayama University Medical School

キーワード

• methotrexate
• polymorphism
• drug elimination
• acute kidney injury
• acute lymphoblastic leukemia

詳細情報

• CRID: 1390296343169640192
• NII論文ID: 120006948942
• NII書誌ID: AA00508441
• ISSN: 0386300X
• DOI: 10.18926/amo/61215
• Web Site: https://ousar.lib.okayama-u.ac.jp/61215
• Web Site: https://search.jamas.or.jp/link/ui/2021248754
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • CiNii Articles